Symbol | Name | Grade | Market Cap | Country |
---|---|---|---|---|
LLY | Eli Lilly and Company | 67.5 | ¤673,574 | US |
JNJ | Johnson & Johnson | 64.4 | ¤431,791 | US |
ABT | Abbott Laboratories | 61.2 | ¤230,768 | US |
MRK | Merck & Co., Inc. | 62.3 | ¤218,231 | US |
TMO | Thermo Fisher Scientific Inc. | 52.0 | ¤188,802 | US |
Symbol | Name | Grade | Market Cap | Country |
---|---|---|---|---|
MOH | Molina Healthcare, Inc. | 47.4 | ¤9,455 | US |
ALGN | Align Technology, Inc. | 47.7 | ¤10,842 | US |
BMRN | BioMarin Pharmaceutical Inc. | 75.5 | ¤11,248 | US |
UTHR | United Therapeutics Corporation | 69.0 | ¤14,121 | US |
COO | Cooper Companies, Inc. | 47.6 | ¤15,007 | US |
Symbol | Name | Grade | Times* | Country |
---|---|---|---|---|
AMGN | Amgen Inc. | 61.9 | 30 | US |
LLY | Eli Lilly and Company | 67.5 | 25 | US |
PFE | Pfizer Inc. | 62.9 | 23 | US |
DGX | Quest Diagnostics Incorporated | 57.8 | 21 | US |
ZTS | Zoetis, Inc. Class A | 59.7 | 21 | US |
JNJ | Johnson & Johnson | 64.4 | 20 | US |
TMO | Thermo Fisher Scientific Inc. | 52.0 | 20 | US |
RMD | ResMed Inc. | 73.0 | 18 | US |
UTHR | United Therapeutics Corporation | 69.0 | 17 | US |
A | Agilent Technologies, Inc. | 50.6 | 15 | US |
Average Market Cap | ¤99,704 |
Median Market Cap | ¤34,551 |
Avg. 3 Mo. Dollar Vol. | ¤530,498,920 |
Avg. 3 Mo. Trading Vol. | 4,004,457 |
Last Rebalance Date | 03/24/2025 |
Companies Replaced | 20 |
Biggest Sector Increase | Health Care |
Biggest Sector Decrease | Health Care |
Trailing P/E Ratio (12 Mo.) | 26.9 |
Forward P/E Ratio (12 Mo.) | 17.9 |
Price/Book Ratio | 4.2 |
Avg. Revenue Chg. - 3 Yr | 9.7% |
Avg. Op. Income Chg. - 3 Yr. | 23.4% |
Avg. EPS Growth - 3 Yr. | 9.6% |
Avg. EPS Growth - 1 Yr. | 9.3% |
Avg. Operating Margin | 23.9% |
Avg. LT Debt to Total Capital | 36.3% |
Avg. Return on Equity | 18.9% |
Dividend Yield | 0% |
US Health Care Index | 59.76 |
United States Of America | 93.33% |
Switzerland | 3.33% |
Ireland | 3.33% |